EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Tus Pharmaceutical Group Co Ltd (000590) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Tus Pharmaceutical Group Co Ltd ¥1.17, price ¥8.97, upside -87.0%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · CN · ISIN CNE000000701

TP Thin data Sep 24, 2026

Tus Pharmaceutical Group Co Ltd

000590 · SHE

Weakest SetupStrongly overvalued and low quality.

!Fair value ¥1.17 · Strongly overvalued (−87%)
!Quality 47/100
!Expensive Growth (revenue 5y +4.2 %/yr)
!Loss-making · -11.9% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (3/12)
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain
!Weak on dividend: 3 out of 100
Watch Tus Pharmaceutical Group Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥14.30 ¥4.90 Fair Value ¥1.17 Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range ¥4.90 – ¥14.30 · fair‑value band ¥0.9700 – ¥1.36 · the ¥8.97 price screens above the ¥1.17 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Tus Pharmaceutical Group Co in your weekly email

Every Wednesday you see whether Tus Pharmaceutical Group Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Guhan Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells traditional Chinese medicines, chemical drugs, and health food under the Guhan brand in China.

Show more

Guhan Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells traditional Chinese medicines, chemical drugs, and health food under the Guhan brand in China. It operates through the Pharmaceutical and Health Product Manufacturing and Sales Business, Active Pharmaceutical Ingredient (API) Manufacturing and Sales Business, and Other Business segments. The company offers prescription and over-the-counter drugs, such as tonics, cardiovascular drugs, children's nutritional supplements, cold and flu remedies, and heat-clearing and detoxifying drugs. It also engages in nutrition and health consulting services; Chinese herbal medicine cultivation; medical research and experimental development; cultural and artistic exchange planning; medical consultation; internet sales; technology promotion, consulting, and agency services; outpatient services; and pharmaceutical wholesale and retail activities. The company was formerly known as Tus-Pharmaceutical Group Co., Ltd. and changed its name to Guhan Pharmaceutical Group Co., Ltd. in November 2025. Guhan Pharmaceutical Group Co., Ltd. was founded in 1956 and is headquartered in Hengyang, China.

Stock analysis

Tus Pharmaceutical Group Co Ltd (000590) currently trades at ¥8.97, while our model-based Fair Value estimate is ¥1.17, implying the stock looks roughly 666.9% overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of ¥1.53 per share, and 0 of the 4 models we run sit above the ¥8.97 price.

Bear case: the Dividend Discount group reads lowest at ¥0.1600, and 4 of the 4 models stay below the price. Evidence for this calculation is low.

Scenario range: ¥0.9700 (bear) to ¥1.36 (bull), the price of ¥8.97 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Tus Pharmaceutical Group Co Ltd reported revenue of 338M CNY in FY2025 versus 301M CNY in FY2021, a compound +2.9%/yr. Reported net income was −50.5M CNY in FY2025.

Key figures

Market cap 2.1B CNY (≈ $320M) · P/S ratio 6.55 · EPS (TTM) ¥−0.1700 · Dividend yield 0.1% · Net margin −15.0% · Return on equity −7.2% · Return on assets (EBIT) −2.1% · Operating margin −8.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 29% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −87%, 000590 screens richer than that median.

Fair Value models

Bear ¥0.9700 Fair Value ¥1.17 Bull ¥1.36
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Gordon GGM ¥0.1100 ¥0.1900 ¥0.2700 67
DDM Multi-Stage ¥0.1100 ¥0.1600 ¥0.2000 67
EV/EBITDA ¥1.12 ¥1.32 ¥1.51 67
All 4 models by family
Dividend Discount
Gordon GGM ¥0.1100 ¥0.1900 ¥0.2700 67
DDM Multi-Stage ¥0.1100 ¥0.1600 ¥0.2000 67
Multiples
EV/EBITDA ¥1.12 ¥1.32 ¥1.51 67
Asset-Based
NCAV (Graham) ¥1.14 ¥1.53 ¥2.29 54

Open the full fair value analysis →

Notify me when 000590 reaches fair value

Put 000590 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 47/100

Of which business quality 49 · Market factors (momentum, volatility) 35

Profitability 10
Margins and returns on capital today
Quality Growth 43
Are margins and returns improving?
Cashflow 13
Earnings quality: real cash, not paper profit
Fin. Strength 89
Balance sheet, leverage, solvency risk
Investment 77
Disciplined investing over empire-building
Low Volatility 78
Calm price path (market factor)
Momentum 19
Price trend over the last 3–12 months (market factor)
52W Momentum 15
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 15/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−1.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
Start year 2020 (pandemic). Over 10 years: +1.4% a year
Revenue growth 33 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
10.1% (2020) → −5.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

000590 screens 667% overvalued. Compare with Merck KGaA →

Compare Tus Pharmaceutical Group Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks

Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside −87% · Bottom 25%
Profitability
Return on assets −1% · Bottom 25%
Net margin (TTM) −12% · Bottom 25%
Operating margin (TTM) −9% · Bottom 25%
Growth and dividend
Revenue growth 10% · Above median
Dividend yield (TTM) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.09× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.59× · Cheapest 25%
P/S (TTM) 0.93× · Cheaper than median
EV/EBITDA 16.4× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)50 · sector 20
PAST (return on equity)0 · sector 27
HEALTH (low debt)95 · sector 96
DIVIDEND (yield)3 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.95 €108.70 −19%
Takeda Pharmaceutical Company TAK $18.81 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.01 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $71.61 $108.48 +51%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Tus Pharmaceutical Group Co Ltd · Fair Value
¥1.17 −667%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Tus Pharmaceutical Group Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/000590.SHE

Frequently asked questions

Is Tus Pharmaceutical Group Co Ltd (000590) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥1.17 versus a price of ¥8.97, about −87% upside (overvalued).
What is the fair value of 000590?
Our model-based fair value for Tus Pharmaceutical Group Co Ltd is ¥1.17 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥8.97.
What is the quality score of 000590?
Tus Pharmaceutical Group Co Ltd has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tus Pharmaceutical Group Co Ltd (000590)?
Our model-based price target is the fair value of ¥1.17 (as of Sep 24, 2026) from 4 valuation models. Cautious scenario ¥0.9700, optimistic scenario ¥1.36. It is a calculation from audited fundamentals, not an analyst target.
What is the Tus Pharmaceutical Group Co Ltd stock forecast for 2026?
Our models put fair value at ¥1.17, about −87% upside versus a price of ¥8.97 (overvalued). Cautious scenario ¥0.9700, optimistic scenario ¥1.36. The calculation is refreshed regularly with new filings.
What is the revenue of Tus Pharmaceutical Group Co Ltd (000590)?
Tus Pharmaceutical Group Co Ltd reported trailing-twelve-month revenue of about 344M CNY (latest available figure, as of Sep 24, 2026).
Does Tus Pharmaceutical Group Co Ltd pay a dividend?
Tus Pharmaceutical Group Co Ltd currently shows a dividend yield of about 0.15% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Tus Pharmaceutical Group Co Ltd (000590)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tus Pharmaceutical Group Co Ltd it is ¥1.17 per share (as of Sep 24, 2026), against a price of ¥8.97. It is the blended result of 4 valuation models (cash flow, earnings, asset, dividend).
Is Tus Pharmaceutical Group Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 000590 trades above its calculated fair value: price ¥8.97, fair value ¥1.17, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 000590?
No. The price is what the market pays today (¥8.97); the fair value is what the company's own numbers justify (¥1.17). For Tus Pharmaceutical Group Co Ltd the two are ¥7.80 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tus Pharmaceutical Group Co Ltd worth?
The market values Tus Pharmaceutical Group Co Ltd at about 2.1B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥8.97; our models calculate a fair value of ¥1.17 per share.
What do the bullish and bearish scenarios say about 000590?
Our models span a range for Tus Pharmaceutical Group Co Ltd: cautious scenario ¥0.9700, base ¥1.17, optimistic ¥1.36 per share (as of Sep 24, 2026, price ¥8.97). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Tus Pharmaceutical Group Co Ltd (000590)?
Balance-sheet figures for Tus Pharmaceutical Group Co Ltd (as of Sep 24, 2026): return on equity −7.2%, debt of 0.09 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 000590 from its 52-week high?
Tus Pharmaceutical Group Co Ltd trades at ¥8.97, about 29% below its 52-week high of ¥12.68 and 16% above the low of ¥7.71 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of ¥1.17 is for.
Which stocks are comparable to Tus Pharmaceutical Group Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tus Pharmaceutical Group Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price ¥8.97, calculated fair value ¥1.17 (−87%), Quality Score 47/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 000590 calculated?
We run Tus Pharmaceutical Group Co Ltd through 4 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥1.17, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Tus Pharmaceutical Group Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tus Pharmaceutical Group Co Ltd (000590)?
The closing price on Sep 24, 2026 was ¥8.97. Our model-based fair value is ¥1.17, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tus Pharmaceutical Group Co Ltd right now?
The price sits above even our optimistic bull case (¥1.36). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Tus Pharmaceutical Group Co Ltd

How large is the market capitalisation of Tus Pharmaceutical Group Co Ltd (000590)?
The market capitalisation of Tus Pharmaceutical Group Co Ltd is 2.1B CNY (≈ $320M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tus Pharmaceutical Group Co Ltd (000590)?
The price-to-sales ratio of Tus Pharmaceutical Group Co Ltd is 6.55 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tus Pharmaceutical Group Co Ltd (000590)?
Earnings per share at Tus Pharmaceutical Group Co Ltd are ¥−0.1700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Tus Pharmaceutical Group Co Ltd (000590)?
The dividend yield of Tus Pharmaceutical Group Co Ltd is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Tus Pharmaceutical Group Co Ltd (000590)?
The net margin of Tus Pharmaceutical Group Co Ltd is −15.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tus Pharmaceutical Group Co Ltd (000590)?
The return on equity (ROE) of Tus Pharmaceutical Group Co Ltd is −7.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tus Pharmaceutical Group Co Ltd (000590)?
On an EBIT basis the return on assets of Tus Pharmaceutical Group Co Ltd is −2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tus Pharmaceutical Group Co Ltd (000590)?
The operating margin of Tus Pharmaceutical Group Co Ltd is −8.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tus Pharmaceutical Group Co Ltd (000590)?
Revenue at Tus Pharmaceutical Group Co Ltd is growing +9.9% versus a year earlier (3y avg −1.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tus Pharmaceutical Group Co Ltd (000590)?
Earnings per share at Tus Pharmaceutical Group Co Ltd are growing +680% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Tus Pharmaceutical Group Co Ltd (000590) generate?
The free cash flow of Tus Pharmaceutical Group Co Ltd is −19.8M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Tus Pharmaceutical Group Co Ltd (000590) hold?
Tus Pharmaceutical Group Co Ltd holds more cash than debt, 92.8M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Tus Pharmaceutical Group Co Ltd in the live analysis

One click puts Tus Pharmaceutical Group Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.